Jian H. Fu

No.8 Of Dianli Road
Zhenjiang, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed death-1 inhibitors in recurrent intermediate and advanced hepatocellular carcinoma: a single-centre retrospective cohort study.

Transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed death-1 inhibitors in recurrent intermediate and advanced hepatocellular carcinoma: a single-centre retrospective cohort study.

Journal: BMC gastroenterology
Published: April 08, 2026

Adverse Reactions of First-Line Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma Treatment: A Descriptive Analysis From WHO-VigiAccess.

Adverse Reactions of First-Line Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma Treatment: A Descriptive Analysis From WHO-VigiAccess.

Journal: International journal of hepatology
Published: June 11, 2025

Adverse drug reaction to tremelimumab and durvalumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database.

Adverse drug reaction to tremelimumab and durvalumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database.

Journal: BMC cancer
Published: June 02, 2025

Quantitative literature analysis on efficacy and safety of balloon-occluded transarterial chemoembolization for hepatocellular carcinoma.

Quantitative literature analysis on efficacy and safety of balloon-occluded transarterial chemoembolization for hepatocellular carcinoma.

Journal: BMC gastroenterology
Published: December 31, 2024

Corrigendum to "Metastasis-associated protein 1, modulated by miR-30c, promotes endometrial cancer progression through AKT/mTOR/4E-BP1 pathway" [Gynecol Oncol. 2019 Jul;154(1):207-217. doi: 10.1016/j.ygyno.2019.04.005. Epub 2019 Apr 9].

Corrigendum to "Metastasis-associated protein 1, modulated by miR-30c, promotes endometrial cancer progression through AKT/mTOR/4E-BP1 pathway" [Gynecol Oncol. 2019 Jul;154(1):207-217. doi: 10.1016/j.ygyno.2019.04.005. Epub 2019 Apr 9].

Journal: Gynecologic oncology
Published: December 13, 2023

Aurora-A Induces Chemoresistance Through Activation of the AKT/mTOR Pathway in Endometrial Cancer.

Aurora-A Induces Chemoresistance Through Activation of the AKT/mTOR Pathway in Endometrial Cancer.

Journal: Frontiers in oncology
Published: February 03, 2019

Metastasis-associated protein 1, modulated by miR-30c, promotes endometrial cancer progression through AKT/mTOR/4E-BP1 pathway.

Metastasis-associated protein 1, modulated by miR-30c, promotes endometrial cancer progression through AKT/mTOR/4E-BP1 pathway.

Journal: Gynecologic oncology
Published: December 23, 2018

miRNA-mRNA Associated With Survival in Endometrial Cancer.

miRNA-mRNA Associated With Survival in Endometrial Cancer.

Journal: Frontiers in genetics
Published: September 29, 2018

Dysregulation of Krüppel-like factor 12 in the development of endometrial cancer.

Dysregulation of Krüppel-like factor 12 in the development of endometrial cancer.

Journal: Gynecologic oncology
Published: August 16, 2018

Percutaneous laser ablation for benign thyroid nodules: a meta-analysis.

Percutaneous laser ablation for benign thyroid nodules: a meta-analysis.

Journal: Oncotarget
Published: December 28, 2016

High expression of transient potential receptor C6 correlated with poor prognosis in patients with esophageal squamous cell carcinoma.

High expression of transient potential receptor C6 correlated with poor prognosis in patients with esophageal squamous cell carcinoma.

Journal: Medical oncology (Northwood, London, England)
Published: April 27, 2013
Showing 1-11 of 11

Last Updated: 09/26/2026